EU Solicits Stakeholder Views On Fairness And Structure Of EMA’s Fee System
Executive Summary
Stakeholders finally have a chance to air their views about the European Medicine Agency’s fee and remuneration system, particularly whether it is “fair, cost-based and not unduly complex.”
You may also be interested in...
Keep It Simple: EU Consults On Future Design Of EMA’s Fee System
Following a report that identified several shortcomings of the European Medicines Agency fee system, the European Commission has suggested various options to make it sustainable and future-proof.
UK Industry ‘Struggling’ With Skill Gaps In AI, Robotics & Data Analytics
A new report says that pharma firms are finding it difficult to recruit staff with experience in emerging scientific technologies, particularly in areas such as regulatory and quality assurance. COVID-19, Brexit and competition for talent with other countries and industry sectors are cited as key factors.
Canada Proposes List Of ‘Critical Products’ & More Agile Regulation To Address Shortages
The Canadian government says stakeholders are “poised for action” to improve the collective response to medical product shortages and has come up with some questions and possible answers as to how best to go about it.